达标治疗策略下别嘌醇与非布司他起始治疗期间痛风发作的比较:一项随机多中心试验的事后分析
该研究为72周随机双盲安慰剂对照非劣效试验的事后分析,纳入940例痛风患者,比较别嘌醇与非布司他达标治疗起始及滴定期间(0至24周)的痛风发作风险。多变量模型显示两种药物发作风险无显著差异(非布司他 vs 别嘌醇 HR 1.17),剂量递增与未递增相比 HR 1.18,亦无显著关联。
要点
- 达标治疗起始别嘌醇或非布司他期间,两者痛风发作风险无显著差异(HR 1.17)。
- 别嘌醇或非布司他剂量递增与未递增相比,发作风险无显著差异(HR 1.18)。
- 发作风险独立相关因素包括较年轻年龄、较高基线血尿酸及无痛风石。
核心结论
- 在采用逐步剂量滴定和最佳实践痛风发作预防的达标治疗策略下,别嘌醇与非布司他起始和滴定期间的痛风发作风险相似。
研究设计与样本
- 一项72周随机、双盲、安慰剂对照、非劣效试验的事后分析,比较别嘌醇与非布司他的疗效。
- 分析0至24周降尿酸治疗起始并滴定至血清尿酸目标低于6 mg/dl(有痛风石者低于5 mg/dl)期间的发作情况。
- 共纳入940例参与者,通过结构化访谈定期评估发作,采用多变量Cox比例风险回归分析发作预测因素。
主要发现
- 参与者平均年龄62.1岁,男性占98.4%,接受别嘌醇或非布司他的比例大致相等,平均基线血清尿酸为8.5 mg/dl。
- 全部参与者均接受抗炎预防,其中90%使用秋水仙碱。
- 多变量模型中,降尿酸治疗药物(非布司他 vs 别嘌醇 HR 1.17)、降尿酸治疗剂量递增(递增 vs 未递增 HR 1.18)、预防类型或个别合并症与痛风发作均无显著关联,且无降尿酸治疗剂量递增交互作用的证据。
- 降尿酸治疗起始/递增期间与发作风险独立相关的因素包括较年轻年龄、较高基线血清尿酸和无痛风石。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Initiating urate-lowering therapy (ULT) in gout can precipitate arthritis flares. There have been limited comparisons of flare risk during the initiation and escalation of allopurinol and febuxostat, administered as a treat-to-target strategy with optimal anti-inflammatory prophylaxis. METHODS: This was a post-hoc analysis of a 72-week randomized, double-blind, placebo-controlled, noninferiority trial comparing the efficacy of allopurinol and febuxostat. For this analysis, the occurrence of flares was examined during weeks 0 to 24 when ULT was initiated and titrated to a serum urate (sUA) goal of less than 6 mg/dl (<5 mg/dl if tophi). Flares were assessed at regular intervals through structured participant interviews. Predictors of flare, including treatment assignment, were examined using multivariable Cox proportional hazards regression. RESULTS: Study participants (n = 940) were predominantly male (98.4%) and had a mean age of 62.1 years with approximately equal proportions receiving allopurinol or febuxostat. Mean baseline sUA was 8.5 mg/dl and all participants received anti-inflammatory prophylaxis (90% colchicine). In a multivariable model, there were no significant associations of ULT treatment (hazard ratio [HR] 1.17; febuxostat vs allopurinol), ULT-dose escalation (HR 1.18 vs no escalation), prophylaxis type, or individual comorbidity with flare and no evidence of ULT-dose escalation interaction. Factors independently associated with flare risk during ULT initiation/escalation included younger age, higher baseline sUA, and absence of tophi. CONCLUSION: These results demonstrate that gout flare risk during the initiation and titration of allopurinol is similar to febuxostat when these agents are administered according to a treat-to-target strategy using gradual ULT-dose titration and best practice gout flare prophylaxis.
引用
- Barry A, Helget LN, Androsenko M, et al. Comparison of Gout Flares With the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-Hoc Analysis of a Randomized Multicenter Trial. Arthritis Rheumatol. 2024. PMID: 38925627. doi:10.1002/art.42927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。